TreatSMA at NICE Conference

So today, Dawn, Gary and Kacper attended the 2019 NICE conference in Manchester. Celebrating 20 years of NICE and attending various sessions on different aspects of the NICE appraisal process and how they plan to make trials more accessible and get drugs quicker to market etc. We were not invited to this event, but as a team, we thought it important that TreatSMA attend.

It was very interesting, and we also asked a few poignant questions after some of the sessions.

We also took along a bound book of pictures and messages that were emailed to TreatSMA, from the many wonderful families, children and adults who participated in our #wearyourhurt campaign on Tuesday 7th May.

A copy of the book was given personally to Sir Andrew Dillon (Chief Executive of NICE), Meindert Boysen (Director of Centre for Health and Technology Appraisal, NICE; pictured, centre left), Helen Knight (Technology Appraisals Programme Director, NICE) and Blake Dark (Commercial Medicines Director, NHS; pictured above, centre right, and below with the book). They have some interesting bedtime reading for tonight.

It was a very interesting and engaging day where they listened and acknowledged our work, especially the many thousands of emails that the community sent to them on #wearyourhurt day. We got the feeling from them that this made a massive impact. So thank you once again for getting involved and taking the time to help with the campaign.

A positive event all round, and now we wait to hear. We have not been told anything else regarding any announcements and do not want to speculate on timeframes. As soon as we know, you will know.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more